Likely strongly supportive because the bill directly reduces out‑of‑pocket prescription costs for patients.

It fits priorities to expand affordability and access for people with high drug needs.

Progressive advocates may still push for lower caps, inclusion of uninsured populations, or complementary measures to control drug prices.

Generally favorable but cautious; sees clear patient benefits while wanting evidence about fiscal and market impacts.

Wants guardrails to avoid unintended premium increases, insurer cost‑shifting, or reduced access to certain drugs.

Would likely support with additional analyses, sunset review, or offsets to limit budget and employer impacts.

Likely opposed; views the mandate as federal overreach into employer and insurance markets.

Concerned it will raise overall health insurance costs, distort plan design, and impose compliance burdens.

Prefers market‑based approaches, targeted assistance, or state-level solutions rather than a broad federal prescription cost cap.